Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed CentralRead more →

Occult breast cancer with axillary lymph-node involvement: mastectomy and chemotherapy

Patient Info: Anonymized, Female, 50s

Biomarkers: Occult breast cancer was ER+/PR+, HER2 IHC 2+

Recurrence-free at 1 year after left nipple-sparing mastectomy, axillary lymph node dissection, and adjuvant chemotherapy for occult breast cancer with axillary nodal involvement.

PubMed CentralRead more →

Stage IV luminal A breast cancer: liver resection and disease-free follow-up

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: luminal A; ER-positive; PgR-positive; HER2-negative

Metastatic Site: lung, liver

Disease-free after R0 hepatic segmentectomy for breast cancer liver metastasis, with May 2021 MRI showing no remaining liver nodules while she continued maintenance letrozole and goserelin.

PubMed CentralRead more →

Stage IV luminal B HER2-negative breast cancer with liver-limited metastasis resected after systemic therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Luminal B; HER2-negative

Metastatic Site: liver

After liver segmentectomy for breast-cancer liver metastasis, follow-up imaging showed no remaining liver nodes, and she remained fit, well, disease-free, and on maintenance letrozole plus goserelin.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Sweitzer, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative; no breast cancer genetic mutation reported

As of December 2024, Marissa had a complete response to treatment and no evidence of cancer after postpartum triple-negative breast cancer involving the breast and lymph nodes was treated with chemotherapy, double mastectomy and 5 weeks of radiation.

Cleveland ClinicRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Juliette's Survivor Story

Patient Info: Juliette Landgrave, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

After egg preservation, 16 rounds of chemotherapy with complete response, lumpectomy, 25 radiation sessions and 1 year of immunotherapy, Juliette was cancer-free as of December 2024.

City of HopeRead more →

Stage III HER2-Positive Breast Cancer Complicated by Systemic Sclerosis During Treatment

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: HER2-positive

At 3-month follow-up after anticancer treatment was stopped, no breast-cancer recurrence or metastasis was detected.

PubMed CentralRead more →

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed CentralRead more →

Breast Cancer and a Separate Intrahepatic Cholangiocarcinoma in a 35-Year-Old Woman

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-positive, HER2/CerbB-2 positive

Breast-cancer care continued with postoperative endocrine maintenance while a separate primary intrahepatic cholangiocarcinoma required additional treatment.

PubMed CentralRead more →

HER2-positive squamous cell breast cancer in complete remission

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: HER2-positive squamous cell breast cancer, ER/PR negative, PD-L1 negative

Clinical complete remission and survival beyond 4 years after mastectomy, AC-TH chemotherapy, and HER2-directed maintenance therapy for Stage IIA HER2-positive primary squamous cell breast cancer.

PubMed CentralRead more →

Rare squamous cell breast cancer: tumorectomy and partial mastectomy

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 21%, triple negative

As of August 2024, she had no recurrence 4 years after surgery, adjuvant AC/docetaxel chemotherapy, and residual breast irradiation for Stage I squamous cell carcinoma of the breast arising in a benign phyllodes tumor.

PubMed CentralRead more →

Secretory breast carcinoma: mastectomy, surveillance, no recurrence at 2 years

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative; PR-negative; HER2-negative

No local recurrence or metastasis after 2 years of follow-up after right mastectomy and axillary lymph-node dissection for triple-negative secretory breast carcinoma.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Nina's Survivor Story

Patient Info: Nina, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; broad hereditary genetic testing negative

Metastatic Site: spine

As of November 2024, Nina described being in a no-evidence-of-disease phase, while continuing treatment because of her Stage IV HER2-positive metastatic breast cancer history.

The Patient StoryRead more →

Breast invasive lobular carcinoma metastatic to the endometrium: hysterectomy and hormone therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 negative, PR/HER2 negative.

Metastatic Site: endometrium (endometrial polyp)

No signs of recurrence were reported 18 months after total hysterectomy with bilateral adnexectomy for endometrial metastasis from invasive lobular breast carcinoma, with scheduled follow-up every 3 to 6 months.

PubMed CentralRead more →

Hormone receptor-positive breast cancer metastatic to the pituitary: surgery and disease-free follow-up

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER 2+; PR 1+; HER2 0; GATA3 positive; CA125 elevated

Metastatic Site: pituitary

Disease-free 11 months after surgical resection of pituitary metastasis from prior hormone receptor-positive, HER2-negative breast cancer, with postoperative recovery supported by antibiotics, hormone replacement/supportive therapy, and electrolyte management.

PubMed CentralRead more →

Brenda's Early-Stage Lobular Breast Cancer Story

Patient Info: Brenda, Female

After double mastectomy and reconstruction, Brenda described herself as cancer-free. She did not require chemotherapy or radiation and remained alert to the possibility of late recurrence.

Lobular Breast Cancer AllianceRead more →

Stage II Triple-Negative Breast Cancer: Italia's Survivor Story

Patient Info: Italia Russell, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA mutation

As of October 2024, Italia had no evidence of disease after Stage II triple-negative breast cancer responded to chemotherapy, the tumor was gone by double mastectomy, and she was completing immunotherapy with 3 infusions left.

Cleveland ClinicRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee, Female, Under 40 | Stage IV

Biomarkers: ER-positive

Metastatic Site: Bones

As of October 2024, Dee was living with Stage IV metastatic ER-positive breast cancer after bone metastases were found in 2023 and had adapted to treatment with ribociclib.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee Doherty, Female, Under 40 | Stage IV

Biomarkers: Hormone-sensitive disease implied by letrozole and ovarian suppression; ER/PR/HER2 status not explicitly stated

Metastatic Site: bone

As of September 2024, Dee was living with Stage IV metastatic breast cancer. Her tumors had not shrunk, but disease was stable on ribociclib/Kisqali, letrozole, and ovarian suppression.

The Patient StoryRead more →

Stage III HER2-Positive Occult Breast Cancer With a Complete Response to Treatment

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HER2-positive

Surgery after neoadjuvant treatment found no residual tumor in the breast or 20 examined lymph nodes, indicating a complete pathologic response; HER2-targeted therapy continued afterward.

PubMed CentralRead more →

Stage IV KRAS Breast Cancer: Lauren's Patient Story

Patient Info: Lauren, Female | Stage IV

Biomarkers: KRAS mutation in colon cancer context

Metastatic Site: Abdominal lining; spine

As of September 2024, Lauren was living with a history of Stage IV colon cancer and recurrent metastatic breast cancer in the spine, with low colon tumor markers, recurring spinal spots, and PET scans every 3 months.

The Patient StoryRead more →

Stage IV Breast Cancer: Lourdes's Patient Story

Patient Info: Lourdes Monje, Under 40 | Stage IV

Metastatic Site: lung

Lourdes is receiving investigational treatment through a clinical trial, with manageable side effects, while continuing to work and spend time with family and friends.